We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 37.54+1.7%Jul 2 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: blessedtobehere who wrote (50206)2/8/2019 7:10:11 PM
From: stockdoc772 Recommendations

Recommended By

  Read Replies (1) of 57069
"Ignore obvious stock manipulation, ignore obvious misleading information by analysts, ignore that we have absolutely no evidence that IMMU didn't meet FDA standards (other than the FDA said so)"

I don't see "obvious" anything. Just a set of facts that leads you to that speculative conclusion. Also, the actual fact that the FDA issued a CRL means they did not meet FDA standards. If you think those standards are inappropriate and the company should have been given a pass anyway, that's your opinion, but not a fact of any sort, and without any evidentiary basis.
In the history of the FDA, they have gotten into trouble many times for approving drugs that should not have been approved, but they have never been in trouble for not approving a drug which should have been. That is the risk benefit calculation that FDA officials make.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext